Trial Profile

Open, multicenter Phase II clinical study for the efficacy and safety of BEBT-908 in the treatment of recurrent or refractory diffuse large b-cell lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jul 2025 According to BeBetter Med media release, BEBT-908 has been officially approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) patients who have received at least two lines of systemic treatment. The company is actively preparing for negotiations to include it in the national medical insurance catalog soon after it's launch.
08 Oct 2023 Status changed from not yet recruiting to active, no longer recruiting.
03 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com